Quantum BioPharma Ltd. (NASDAQ: QNTM) has received U.S. Food and Drug Administration clearance of its Investigational New Drug application to initiate a randomized, double-blind, placebo-controlled Phase 2 trial of Lucid-MS in people with multiple sclerosis. The clearance, highlighted in recent editorial coverage, represents the first clinical testing of Lucid-MS in patients with MS and positions the company among a select group of developers pursuing myelin repair rather than broad immune suppression.
Lucid-MS, also known as Lucid-21-302, is a patented, first-in-class drug candidate designed to inhibit peptidyl arginine deiminase 2 (PAD2). By targeting PAD2, the compound aims to address demyelination—the underlying mechanism of MS—rather than simply modulating the immune system. In preclinical models, Lucid-MS has been shown to prevent and reverse myelin degradation. The drug previously completed Phase 1 testing in healthy volunteers, with the company reporting favorable safety and tolerability. The upcoming Phase 2 trial will be the first to evaluate the candidate in people living with MS.
The FDA clearance carries significant implications for the MS treatment landscape. Existing therapies largely focus on controlling inflammation and reducing relapse rates, but none have been approved to repair damaged myelin. If Lucid-MS succeeds in clinical testing, it could offer a complementary or alternative approach for patients, particularly those with progressive forms of MS who have limited treatment options. The trial’s design—randomized, double-blind, and placebo-controlled—is the gold standard for establishing efficacy and safety, and its outcomes will be closely watched by investors and clinicians alike.
Quantum BioPharma is also pursuing a parallel research collaboration with scientists at Massachusetts General Hospital and Harvard Medical School. That work involves a PET imaging tracer designed to quantify demyelination, which could provide a biomarker for assessing treatment response and accelerate the development of remyelinating therapies. Such a tool would be valuable not only for Quantum but for the broader field, as it could help standardize how myelin damage and repair are measured in clinical trials.
Analyst attention has followed the regulatory progress. Rodman & Renshaw recently initiated coverage of Quantum BioPharma with a Buy rating and an $8 price target, reflecting optimism about Lucid-MS as the company prepares for its first MS patient testing. The editorial coverage also placed Quantum alongside larger biopharmaceutical developments involving Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), and Clene Inc. (NASDAQ: CLNN), spanning vaccines, ophthalmology, and neurological diseases. For Quantum, the FDA clearance is a validating milestone that could raise its profile in the competitive neuroimmunology space.
Quantum BioPharma describes itself as a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. Quantum also invented UNBUZZD and spun out its over-the-counter version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, along with royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
For investors and patients, the FDA clearance is more than a procedural step. It signals that Lucid-MS has cleared the initial safety hurdle and can now be tested in the population that matters most. If the Phase 2 trial demonstrates evidence of remyelination or clinical benefit, Quantum BioPharma could become a notable player in a field where few companies have advanced candidates. The results will also inform the broader scientific effort to treat MS by repairing the nervous system, not just suppressing it.
